Budget impact of introducing an omalizumab biosimilar in 23 European countries.
Saved in:
| Title: | Budget impact of introducing an omalizumab biosimilar in 23 European countries. |
|---|---|
| Authors: | Jang M; Celltrion, Inc, Incheon, Republic of Korea., Lee J; Celltrion, Inc, Incheon, Republic of Korea., Yi S; Celltrion, Inc, Incheon, Republic of Korea., Kwon TS; Celltrion, Inc, Incheon, Republic of Korea. |
| Source: | Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1639-1650. Date of Electronic Publication: 2025 Sep 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
